• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » State appeals court reverses preempted Medtronic InFuse case

State appeals court reverses preempted Medtronic InFuse case

January 31, 2014 By Brad Perriello

State appeals court reverses preemped Medtronic InFuse case

A California appeals court this week reanimated a product liability lawsuit filed over Medtronic‘s (NYSE:MDT) controversial InFuse bone-growth protein, reversing a lower court’s decision that federal regulations in this case preempt state rules.

The preemption doctrine is based on a U.S. Supreme Court ruling that state laws that differ from or add to federal regulations are trumped by the federal rules. The high court included a caveat, however: in some cases, claims citing state laws that exactly parallel the federal rules are allowed. The California Court of Appeal took that caveat into account in its January 27 decision, partially overturning a lower state court ruling that plaintiff John Coleman’s claims were preempted.

Coleman was implanted with the InFuse product in April 2009 in a posterior fusion operation, according to court documents. InFuse is approved only for anterior fusion procedures. Coleman allegedly suffered from numbness and pain after the surgery; CT scans revealed that the bone-morphogenetic material in the InFuse implant had spurred bone growth that "encased the nerves in Coleman’s spine," according to the documents.

Coleman’s lawsuit was initially dismissed when the lower court agreed with Medtronic’s preemption argument. Coleman’s appeal relied in part a U.S. Court of Appeals for the 9th Circuit decision that parallel state claims are not preempted by federal rules. Coleman argued that Medtronic is liable for failing to warn about adverse events associated with InFuse and for promoting its off-label use.

The appeals court agreed with enough of the argument to keep Coleman’s suit alive, ruling that federal laws covering how medical device companies must report adverse events are parallel with California’s liability laws on failure to warn, according to the documents.

"California law imposes a parallel requirement under the common law strict liability tort of failure to warn. The device manufacturer can be found liable if it ‘did not adequately warn of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution,’" the state appeals court ruled.

The appeals court used the same reasoning in its decision that 2 of Coleman’s claims for negligence, 1 based on failure to warn of adverse events and the 2nd on off-label promotion, are similarly not preempted. But the court disagreed with another of Coleman’s claims, failure to warn on the grounds of off-label promotion.

"In our view, Coleman’s failure to warn claim cannot include a theory of off-label promotion because he would inherently be claiming that by promoting the off-label use of Infuse, Medtronic incurred a duty to warn plaintiff and his doctors about the risks of such use. Because Medtronic has already complied with federal requirements for warnings and labeling, any state law requirement to provide additional warnings would be different from, and in addition to, federal requirements," according to the documents. "Federal regulations prevent device manufacturers from promoting off-label use of FDA-approved devices. Those requirements are substantively different than the requirements imposed by California common law in the failure to warn context."

The court demurred on a 3rd claim for manufacturing defect, ruling that it was too early in the proceedings for a proper ruling on whether the state law parallels federal law.

The California appeals bench sent the Coleman case back to the Los Angeles County Superior Court for reconsideration of the 3 claims it upheld, awarding costs on appeal to the plaintiff.

"The judgment is reversed to the extent the trial court sustained the demurrer to the 3rd amended complaint without leave to amend as to the causes of action for (1) strict liability failure to warn based on a failure to warn the FDA theory, (2) negligence, and (3) design defect. We remand the case for further proceedings. Costs on appeal are awarded to Coleman," according to the documents.

Filed Under: Legal News, News Well Tagged With: Minnesota, Personal Injury, Resorbable bone materials

In case you missed it

  • First OTC molecular test for COVID-19 gains FDA nod
  • Private equity firm GTCR forms Epselon Global to acquire healthcare businesses
  • Former Abbott sales director’s age discrimination suit can proceed
  • Second Sight gains FDA nod for retinal system that may never be produced
  • Abbott wins EUA for COVID-19, flu, RSV combo assay
  • Colfax to split to create new orthopedic device giant
  • Iridex, Topcon seal eye care deal
  • SmileDirectClub dips on missed Q4 projections
  • MedAlliance nabs FDA breakthrough nod for drug-eluting coronary balloon
  • Medtronic launches DCB for dialysis patients in Japan
  • Acuitive Technologies gains FDA nod for ligament reconstruction devices
  • Alphatec posts mixed-bag Q4 results
  • Senseonics sinks on mixed bag Q4, massive bottom-line slide
  • Asensus Surgical finalizes name change from TransEnterix, debuts NYSE ticker
  • Organ-chips could streamline drug development, but hurdles remain
  • Ivermectin not supported for mild COVID-19, study says
  • ControlRad gains clearance for imaging tech to sell to Boston Sci

RSS From Medical Design & Outsourcing

  • First OTC molecular test for COVID-19 gains FDA nod
    The FDA today issued its first emergency use authorization for a molecular COVID-19 diagnostic test for at-home use without a prescription. The Cue Health COVID-19 Test for Home and Over The Counter (OTC) use is a molecular nucleic acid amplification test designed to detect genetic material from the SARS-CoV-2 virus in the nostrils. The authorized… […]
  • A wearable jaundice monitor for newborns?
    Researchers in Japan say they have developed the first wearable device to precisely monitor jaundice, a yellowing of the skin caused by elevated bilirubin levels in the blood that can cause severe medical conditions — even death — in newborns. Jaundice can be treated easily by irradiating the infant with blue light that breaks bilirubin… […]
  • Plastikos to double size of medical manufacturing operation
    Plastikos announced today that the second phase of construction on its Plastikos Medical plant will begin this month. The Erie, Pa.-based company completed the first building in its medical business in 2019 and has added 10 medical injection molding machines since then. The second building will more than double the size of the current ISO-7 cleanroom… […]
  • Paxxus sealant updated for EU-MDR
    Paxxus announced this week that its Chameleon color-changing package seal indicator technology now works with uncoated Tyvek used to package medical devices. Addison, Ill.-based Paxxus said it updated the technology in advance of a new packaging regulation set to go into effect in the EU in May. Chameleon now shows a vivid color-seal indicator when… […]
  • Medtronic hiring Walmart exec to run its supply chain
    Medtronic (NYSE:MDT) CEO Geoff Martha announced that the company is appointing Greg Smith as EVP of global operations and supply chain. In a LinkedIn post today, Martha wrote: “I’m pleased to share that Greg Smith, Executive Vice President of U.S. Supply Chain for Walmart, is joining Medtronic on April 5 as Executive Vice President of… […]
  • Philips and Disney want to make MRIs easier for children: Here’s how
    Royal Philips (NYSE:PHG) announced today that it is teaming up with Disney to test the effects of custom-made animation to create a relaxing atmosphere for young patients. Amsterdam-based Philips will collaborate with The Walt Disney Company EMEA to see whether the animation, including specially-made Disney stories within Philips’ Ambient Experience, creates a relaxing atmosphere to improve… […]
  • Origami Surgical gains FDA clearance for robotic suturing devices
    Origami Surgical today announced that the FDA has granted 510(k) clearance for three new types of sutures for its StitchKit robotic surgery platform. The company describes StitchKit as a patented suture delivery and retrieval system designed so sutures are efficiently inserted and needles are safely removed from the surgical field. StitchKit also allows the robotic… […]
  • NAMSA acquires American Preclinical Services
    Contract research organization NAMSA today announced its acquisition of Minneapolis-based American Preclinical Services (APS). This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January. The acquisition will provide NAMSA customers with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs,… […]
  • 5 reasons Medtronic’s CEO is optimistic about the future
    Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming. In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more. Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are… […]
  • Medtronic is changing a lot: Here’s what you need to know
    CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere. In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s… […]
  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS